Skip to main content

ImmunoGen Value Stock - Dividend - Research Selection

ImmunoGen

ISIN: US45253H1014, WKN: 878613

Market price date: 24.05.2021
Market price: 6,40 USD




ImmunoGen Fundamental data and company key figures of the share

Annual reports in USD
Key figures 05-03-2021
Cash flow
Net operating cash flow -78.620.000
Capital Expenditures -917.000
Free cash flow -79.537.000
Balance sheet
Total Equity 89.570.000
Liabilities & Shareholders equity 355.072.000
Income statement
Net income -44.372.000
Eps (diluted) -0,250
Diluted shares outstanding 194.710.000
Net sales/revenue 132.299.000

Fundamental ratios calculated on: 24-05-2021

Ratios
Key figures 24-05-2021
Cash flow
P/C -15,11
   
P/FC -14,93
Balance sheet
ROI-12,50
ROE25,23
Income statement
P/E-24,40
Div. Yield0,00%
P/B13,26
P/S8,98


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolIMGN
Market Capitalization1.187.730.944,00 USD
Country
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.immunogen.com


Description of the company

ImmunoGen, Inc. (ImmunoGen) develops targeted, antibody-based therapeutics for the treatment of cancer. ImmunoGen designs linkers that enable antibody-based therapeutics for the treatment of cancer agents to remain stably attached to the antibodies while in the blood stream and be released in their fully active form after delivery to a cancer cell. An anticancer compound made using the Company´s Targeted Antibody Payload (TAP), technology consists of a monoclonal antibody. The Company´s TAP technology is designed to enable the creation of well-tolerated anticancer products. As of June 30, 2012, ImmunoGen had three wholly owned clinical-stage product candidates included IMGN901, IMGN853, and IMGN529, and other TAP compounds in earlier stages of development.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.immunogen.com